Remove Engineer Remove Recombinant Antibody Remove Trials
article thumbnail

Grifols’ Innovation Strategy in the Plasma Medicine Space

XTalks

It’s all part of a deep-seated commitment to innovation and its role as the company’s growth engine. Our pipeline, for example, includes a new class of recombinant antibodies. Right now, they are doing what is probably the most advanced work in the field of polyclonal recombinant antibody therapies.

Medicine 111
article thumbnail

Transgene and BioInvent Receive Approval From ANSM to Proceed With Phase I/IIa Trial of Anti-CTLA4-armed Oncolytic Virus BT-001 in Solid Tumors

The Pharma Data

The first patient is expected to be enrolled in this trial in the upcoming weeks. oncolytic virus (VVcopTK-RR-), and has been engineered to encode both a Treg-depleting human recombinant anti-CTLA4 antibody generated by BioInvent’s proprietary n-CoDeR®/F.I.R.S.T BT-001 is based on the patented Invir.IO

Trials 40